摘要
目的探讨PDCA循环法在提高住院患者抗菌药物治疗前病原学送检率中的应用效果。方法利用医院信息系统和杏林医院感染管理系统选取2021年1月至12月(PDCA管理前)以治疗为目的的全身性使用抗菌药物的住院患者37124例,使用特殊级抗菌药物的住院患者7837例,使用限制级抗菌药物的住院患者29493例,作为对照组;选取2022年1月至12月(PDCA管理后)的上述患者各26558例、7919例、24433例,作为观察组。运用PDCA循环法,通过调查现状、分析原因、制订计划、实施方案等步骤对抗菌药物治疗前病原学送检率进行全方位管理,比较管理前后住院患者抗菌药物治疗前病原学送检率的差异。结果观察组全身性抗菌药物、特殊级抗菌药物、限制级抗菌药物病原学送检率分别为60.86%,97.34%,89.50%,均显著高于对照组的56.61%,86.91%,64.29%(P<0.001)。结论PDCA循环法能有效提高住院患者抗菌药物治疗前病原学送检率。
Objective To investigate the application effect of PDCA cycle method in improving the pathogen detection rate of inpatients before antimicrobial treatment.Methods Through the hospital information system and the xinglin hospital infection management information system,select 37124 inpatients with systemic use of antibiotics,7837 inpatients with special grade antibiotics and 29493 inpatients with restricted grade antibiotics in the hospital from January to December 2021(before PDCA management)for therapeutic purposes were selected as the control group,26558 inpatients with systemic use of antibiotics,7919 inpatients with special grade antibiotics and 24433 inpatients with restricted grade antibiotics in the hospital from January to December 2022(after PDCA management)for therapeutic purposes were selected as the observation group.PDCA cycle method was used to comprehensively manage the pathogen detection rate before antimicrobial treatment by investigating the current situation,analyzing the reasons,formulating plans,implementing plans,and other steps.The differences in the pathogen detection rate before and after antimicrobial treatment in inpatients were compared.Results After management,the pathogen detection rates of systemic antibiotics,special grade antibiotics,and restricted grade antibiotics in the observation group were 60.86%,97.34%,and 89.50%,which were significantly higher than 56.61%,86.91%,and 64.29%in the control group(P<0.001).Conclusion PDCA cycle management tool can effectively improve the pathogen detection rate of inpatients before antimicrobial treatment.
作者
王潋漪
杨燕
李双玉
陈志美
WANG Lianyi;YANG Yan;LI Shuangyu;CHEN Zhimei(The Second Affiliated Hospital of Chongqing Medical University,Chongqing,China 400010)
出处
《中国药业》
CAS
2024年第9期145-148,共4页
China Pharmaceuticals
基金
重庆市卫生健康委员会医学科研项目[2023WSJK027]。